Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term outcomes after ABT-450/r/ABT-267 + ABT-333 with or without ribavirin in adults with genotype 1 chronic hepatitis C
2014-001022-14Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of paritaprevir, ritonavir, glecaprevir, dasabuvir, ribavirin in hepatitis C virus infection, sponsored by AbbVie Inc.. Started Aug 2014; status: completed.
02
Drugs
paritaprevirritonavirglecaprevirdasabuvirribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2014-001022-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001022-14.